BlueYard × Nucleate Partnership Announcing the 2023 Venture Prize Winners
We are excited to share that Fusix Biotech is one of winners of the 2023 Nucleate Venture Prize funded by BlueYard Capital. Read more on Blueyard.medium.com
10th BioAngels Virtual Pitch
We are grateful for the chance to present at BioM's BioAngels event in front of venture capital investors, business angels and other private investors who invest in life sciences & health tech start-ups.
m4 Award 2019
Oncolytic viruses (OVs) now claim a steadily growing market share in cancer therapeutics. These viruses offer an elegant and multimodal mode of action that enables a long-lasting systemic therapeutic success. m4 Award 2019 PD Dr. Jennifer Altomonte Teresa Krabbe Klinikum rechts der Isar, Technical University of Munich Commercialization of oncolytic viruses (FUSIX Biotech) Oncolytic [...]
